Watch our Latest Webinar: "Unlocking the Glycoproteome: Utilizing a Robust AI/ML Based Platform for Biomarker Discovery"

NEWS AND EVENTS

GO BACK
InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.

The members of InterVenn’s executive leadership team will be available for one-on-one meetings at the event. A live and archived webcast of the event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/ following the forum.

 

InterVenn Contact
Ramuné Carothers
Vice President, Corporate Communications
InterVenn Biosciences
media@venn.bio

Investor Contact
David Deuchler, CFA
Gilmartin Group
ir@venn.bio

Get in touch